VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatmentSteven G. Patten, Brenda L. Coomber|BMC Cancer|2010Cited by 33
Molecular blockade of VEGFR2 in human epithelial ovarian carcinoma cellsSirin A. Adham, Brenda L. Coomber|Laboratory Investigation|2010Cited by 30
Modulation of the Tumor Suppressor Protein α-Catenin by Ischemic MicroenvironmentClaire Plumb, Brenda L. Coomber|American Journal Of Pathology|2009Cited by 8
Lack of Efficacy of Combined Antiangiogenic Therapies in Xenografted Human MelanomaUna Adamcic, Brenda L. Coomber|Journal of Oncology|2011Cited by 0